Literature DB >> 10895428

Epidemiology of hepatitis C: geographic differences and temporal trends.

A Wasley1, M J Alter.   

Abstract

Hepatitis C Virus (HCV) infection appears to be endemic in most parts of the world, with an estimated overall prevalence of 3%. However, there is considerable geographic and temporal variation in the incidence and prevalence of HCV infection. Using age-specific prevalence data, at least three distinct transmission patterns can be identified. In countries with the first pattern (e.g., United States, Australia), most infections are found among persons 30-49 years old, indicating that the risk for HCV infection was greatest in the relatively recent past (10-30 years ago) and primarily affected young adults. In countries with the second pattern (e.g., Japan, Italy), most infections are found among older persons, consistent with the risk for HCV infection having been greatest in the distant past. In countries with the third pattern (e.g., Egypt), high rates of infection are observed in all age groups, indicating an ongoing high risk for acquiring HCV infection. In countries with the first pattern, injection drug use has been the predominant risk factor for HCV infection, whereas in those with the second or third patterns, unsafe injections and contaminated equipment used in healthcare-related procedures appear to have played a predominant role in transmission. Much of the variability between regions can be explained by the frequency and extent to which different risk factors have contributed to the transmission of HCV. Because different strategies are required to interrupt different patterns of HCV transmission, determining the epidemiology of HCV infection in areas where that information has not yet been assessed is critical for developing appropriate prevention programs.

Entities:  

Mesh:

Year:  2000        PMID: 10895428     DOI: 10.1055/s-2000-9506

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  234 in total

Review 1.  Hepatitis C in pregnancy.

Authors:  N Hadzić
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropismatic infection by hepatitis C virus.

Authors:  Fumi Kobayashi; Shuhei Yamada; Shuhei Taguwa; Chikako Kataoka; Satomi Naito; Yoshiki Hama; Hideki Tani; Yoshiharu Matsuura; Kazuyuki Sugahara
Journal:  Glycoconj J       Date:  2012-06-03       Impact factor: 2.916

3.  Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.

Authors:  David R Nelson; Stefan Zeuzem; Pietro Andreone; Peter Ferenci; Robert Herring; Donald M Jensen; Patrick Marcellin; Paul J Pockros; Maribel Rodríguez-Torres; Lorenzo Rossaro; Vinod K Rustgi; Thomas Sepe; Mark Sulkowski; Isaac R Thomason; Eric M Yoshida; Anna Chan; George Hill
Journal:  Ann Hepatol       Date:  2012 Jan-Feb       Impact factor: 2.400

Review 4.  Treatment of hepatitis C in 2011: what can we expect?

Authors:  Mitchell L Shiffman
Journal:  Curr Gastroenterol Rep       Date:  2010-02

5.  Prevalence of hepatitis C virus antibody among undergraduates in ogbomoso, southwestern Nigeria.

Authors:  Abiodun Christopher Jemilohun; Bolaji Oyetunde Oyelade; Sebastine Oseghae Oiwoh
Journal:  Afr J Infect Dis       Date:  2014

6.  Detection of novel biomarkers of liver cirrhosis by proteomic analysis.

Authors:  Christian Mölleken; Barbara Sitek; Corinna Henkel; Gereon Poschmann; Bence Sipos; Sebastian Wiese; Bettina Warscheid; Christoph Broelsch; Markus Reiser; Scott L Friedman; Ida Tornøe; Anders Schlosser; Günter Klöppel; Wolff Schmiegel; Helmut E Meyer; Uffe Holmskov; Kai Stühler
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

7.  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.

Authors:  Masao Omata; Haruhiko Yoshida; Joji Toyota; Eiichi Tomita; Shuhei Nishiguchi; Norio Hayashi; Shiro Iino; Isao Makino; Kiwamu Okita; Gotaro Toda; Kyuichi Tanikawa; Hiromitsu Kumada
Journal:  Gut       Date:  2007-06-15       Impact factor: 23.059

Review 8.  Viral hepatitis: new data on hepatitis C infection.

Authors:  Erzsébet Szabó; Gábor Lotz; Csilla Páska; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

9.  Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death.

Authors:  Guaniri Mateu; Ruben O Donis; Takaji Wakita; Jens Bukh; Arash Grakoui
Journal:  Virology       Date:  2008-05-02       Impact factor: 3.616

10.  Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Authors:  Henry Radziewicz; Chris C Ibegbu; Huiming Hon; Melissa K Osborn; Kamil Obideen; Mohammad Wehbi; Gordon J Freeman; Jeffrey L Lennox; Kimberly A Workowski; Holly L Hanson; Arash Grakoui
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.